Quantcast
Last updated on April 24, 2014 at 12:23 EDT

Latest Multiple Myeloma Research Foundation Stories

2012-10-27 23:20:06

NORWALK, Conn., Oct. 28, 2012 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) joined forces with some of the biggest names in the music industry in its ongoing fight against cancer at the 15(th) Anniversary MMRF Fall Gala last night. All funds raised at this special event, which took place at the Hyatt Regency Greenwich in Old Greenwich, CT, will support the development of life-extending treatments for multiple myeloma, an incurable blood cancer. The event, co-chaired by...

2012-09-27 23:03:53

Mitch Vazquez, an enthusiastic philanthropic donor offers aid to the Advance Cancer Research philanthropy. He is an active benefactor helping number of regional causes in their act to make the world a better place for some underprivileged people. (PRWEB) September 27, 2012 Mitch Vazquez, an enthusiastic philanthropic donor offers aid to the Advance Cancer Research philanthropy. He is an active benefactor helping number of regional causes in their act to make the world a better place for...

2012-07-25 02:31:24

SOUTH SAN FRANCISCO, Calif., July 25, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Blood, the medical journal of the American Society of Hematology, has published results from the 003-A1 Phase 2b trial, a single-arm, multicenter clinical trial evaluating Kyprolis(TM) (carfilzomib) for Injection for the treatment of patients with advanced multiple myeloma, who had received a median of five prior anti-myeloma regimens. The lead author was Dr. David Siegel,...

2012-06-04 02:24:33

CHICAGO, June 4, 2012 /PRNewswire/ -- A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA. The researchers, led by Andrzej J. Jakubowiak, M.D., Ph.D., professor of medicine and director of the multiple myeloma...

2011-12-14 08:00:00

NORWALK, Conn. and SOUTH SAN FRANCISCO, Calif., Dec. 14, 2011 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the start of a multi-year collaboration in support of the comprehensive research initiative in personalized medicine sponsored by the MMRF. The MMRF's Personalized Medicine Initiative, the largest research effort ever undertaken against this incurable disease, is designed to enable the molecular...

2011-12-12 20:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced final results from a Phase 2 study, known as the 004 study, evaluating single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma. Results on prolonged infusion of carfilzomib and speed of response were also announced. These data were presented at the 53rd American Society of Hematology (ASH) Annual...

2011-12-12 16:45:00

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center. Jakubowiak will present final results of the phase I-II study on Dec. 12, 2011, at the American...

2011-12-12 12:50:55

Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego. The drug thalidomide achieved infamy in the early 1960s as the cause of severe birth defects after being given to pregnant mothers for...

2011-12-11 19:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma. The Prescription Drug User Fee Act (PDUFA) date for completion of review by the FDA of the NDA is July 27, 2012. In the NDA filing...

2011-12-10 20:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA. "This expanded data set supports our belief in the potential of carfilzomib to treat late-stage patients with...